PT1169057E - Vacina anti-hiv-1 compreendendo o todo ou parte de uma proteina tat de vih-1 - Google Patents

Vacina anti-hiv-1 compreendendo o todo ou parte de uma proteina tat de vih-1

Info

Publication number
PT1169057E
PT1169057E PT00918952T PT00918952T PT1169057E PT 1169057 E PT1169057 E PT 1169057E PT 00918952 T PT00918952 T PT 00918952T PT 00918952 T PT00918952 T PT 00918952T PT 1169057 E PT1169057 E PT 1169057E
Authority
PT
Portugal
Prior art keywords
hiv
vaccine
comprehending
whole
tat protein
Prior art date
Application number
PT00918952T
Other languages
English (en)
Inventor
Loret Erwann
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9904610A external-priority patent/FR2792204B1/fr
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Publication of PT1169057E publication Critical patent/PT1169057E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT00918952T 1999-04-13 2000-04-12 Vacina anti-hiv-1 compreendendo o todo ou parte de uma proteina tat de vih-1 PT1169057E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9904610A FR2792204B1 (fr) 1999-04-13 1999-04-13 Vaccin anti-vih-1 comprenant tout en partie de la proteine tat de vih-1
FR9916633A FR2792206B1 (fr) 1999-04-13 1999-12-29 Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1

Publications (1)

Publication Number Publication Date
PT1169057E true PT1169057E (pt) 2005-03-31

Family

ID=26234914

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00918952T PT1169057E (pt) 1999-04-13 2000-04-12 Vacina anti-hiv-1 compreendendo o todo ou parte de uma proteina tat de vih-1

Country Status (20)

Country Link
US (1) US7087377B2 (pt)
EP (1) EP1169057B1 (pt)
JP (1) JP4860823B2 (pt)
KR (1) KR100725637B1 (pt)
AT (1) ATE280586T1 (pt)
AU (1) AU775560B2 (pt)
BR (1) BR0009758A (pt)
CA (1) CA2370563C (pt)
DE (1) DE60015312T2 (pt)
DK (1) DK1169057T3 (pt)
ES (1) ES2231178T3 (pt)
FR (1) FR2792206B1 (pt)
HK (1) HK1044463B (pt)
HU (1) HUP0200841A2 (pt)
IL (2) IL145884A0 (pt)
MX (1) MXPA01010482A (pt)
NO (1) NO326603B1 (pt)
PL (1) PL197666B1 (pt)
PT (1) PT1169057E (pt)
WO (1) WO2000061067A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100465589B1 (ko) * 2001-04-20 2005-01-13 허만욱 비만 억제 폴리펩타이드
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
PL2293810T3 (pl) 2008-04-22 2014-11-28 Univ Aix Marseille Zmutowane białko Tat Oyi do zapobiegania lub leczenia AIDS
AU2010230073B2 (en) * 2009-03-23 2016-05-26 Pin Pharma, Inc. Treatment of cancer with immunostimulatory HIV Tat derivative polypeptides
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2011128720A1 (en) * 2010-04-14 2011-10-20 Mymetics Corporation Trans-activator of transcription protein
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
CA2894166A1 (en) 2012-12-06 2014-06-12 Pin Pharma, Inc. Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
AU2014329393B2 (en) 2013-10-04 2020-04-30 Pin Pharma, Inc. Immunostimulatory HIV Tat derivative polypeptides for use in cancer treatment
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US5019510A (en) 1987-10-28 1991-05-28 Institut Pasteur Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
US5132205A (en) * 1988-10-07 1992-07-21 Eastman Kodak Company High ph extraction composition and its use to determine a chlamydial, gonococcal or herpes antigen
US5461029A (en) * 1992-04-24 1995-10-24 American Cyanamid Company Method of treating herpes viral infections using HBNF and MK proteins
FR2700169B1 (fr) * 1993-01-04 1995-03-24 Transgene Sa Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
EP0814834B2 (fr) * 1995-03-08 2009-03-18 Neovacs Immunogenes denues de toxicite derivant d'une proteine de regulation retrovirale, anticorps diriges contre ces immunogenes, procede pour leur preparation et compositions pharmaceutiques les renfermant
DE19514089C2 (de) * 1995-04-13 1997-07-10 Deutsches Krebsforsch Nachweisverfahren für HIV-TAT
JPH10212300A (ja) * 1996-11-26 1998-08-11 Sankyo Co Ltd ペプチドワクチン
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1

Also Published As

Publication number Publication date
ES2231178T3 (es) 2005-05-16
EP1169057A2 (fr) 2002-01-09
US7087377B2 (en) 2006-08-08
WO2000061067A2 (fr) 2000-10-19
FR2792206A1 (fr) 2000-10-20
HK1044463A1 (en) 2002-10-25
PL197666B1 (pl) 2008-04-30
PL353033A1 (en) 2003-10-06
JP4860823B2 (ja) 2012-01-25
HK1044463B (zh) 2005-06-03
EP1169057B1 (fr) 2004-10-27
NO326603B1 (no) 2009-01-19
IL145884A0 (en) 2002-07-25
KR20020005675A (ko) 2002-01-17
BR0009758A (pt) 2002-01-08
MXPA01010482A (es) 2002-09-18
KR100725637B1 (en) 2007-06-07
HUP0200841A2 (en) 2002-07-29
NO20014841D0 (no) 2001-10-04
IL145884A (en) 2007-09-20
CA2370563C (fr) 2013-12-17
ATE280586T1 (de) 2004-11-15
NO20014841L (no) 2001-11-27
US20050106161A1 (en) 2005-05-19
WO2000061067A3 (fr) 2001-03-29
DE60015312D1 (de) 2004-12-02
JP2002541165A (ja) 2002-12-03
WO2000061067B1 (fr) 2001-05-10
DE60015312T2 (de) 2006-02-09
DK1169057T3 (da) 2005-03-07
AU775560B2 (en) 2004-08-05
CA2370563A1 (fr) 2000-10-19
AU3972400A (en) 2000-11-14
FR2792206B1 (fr) 2006-08-04

Similar Documents

Publication Publication Date Title
PT1169057E (pt) Vacina anti-hiv-1 compreendendo o todo ou parte de uma proteina tat de vih-1
TR199801418T2 (xx) Rekombinant a�� vekt�rleri kar���m�.
BR0014282A (pt) Vacinas
ATE380822T1 (de) Funf-helix protein
CY1108007T1 (el) Φαρμακευτικες συνθεσεις βοτουλινικης τοξινης
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
DE69838986D1 (de) Polypeptide, deren herstellung und verwendung
ATE315667T1 (de) Amplifizierung und detektion von hiv-1 und/oder hiv-2
EA199901031A1 (ru) Производные бензимидазола
MXPA02007478A (es) Vacuna contra el virus de inmunodeficiencia humana.
DE60023300D1 (de) Verwendung von cpg als adjuvans für hivimpstoff
DE69938935D1 (de) Zyklische conotoxin-peptide
ES2191075T3 (es) 8-arilalquil- y 8-arilheteroalquil-5,11-dihidro-6h-dipirido-(3,2-b:2',3'-e)(1,4)diazepinas y su uso en la prevencion o tratamiento de infecciones por hiv.
BR0108056A (pt) Preparados cosméticos com extratos waltheria indica
DK1343896T3 (da) Lille syreoplöseligt sporeprotein og anvendelser deraf
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
DK1301637T3 (da) DNA-vacciner, der koder for HIV accessoriske proteiner
ATE238791T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure als mukolytikum
ATE241640T1 (de) Fusidinsäure-derivate
ZA200108398B (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein.
ATE349532T1 (de) Zytotoxisches t-zellepitop des papillomavirus l1- proteins und seine verwendung in diagnostik und therapie
HUP9904262A2 (hu) Fehérjék alkalmazása retrovírus elleni szerként
FR2834717B1 (fr) Mutants de la proteine tat du virus vih-1
BR0109345A (pt) Compostos com atividade anti-hiv
HUP0303423A2 (hu) HIV elleni természetes ellenanyag